Dendreon Corp. (DNDN-NASDAQ) was downgraded from an “Outperform” rating to a “Market Perform” rating. The brokerage sees uncertainties and risks going into an expected meeting FDA meeting over the recent “approvable and request for more data” on its Provenge for the treatment of late-stage prostate cancer. It was back around April 11 that JMP downgraded the shares to an Outperform rating. Shares are trading down about 3% at $6.62 in pre-market trading.
Jon C. Ogg May 24, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.
If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
